Retinoid X receptor-interacting polypeptides

US5932699A · kind A · utility

Assignee

• The General Hospital Corporation · US

Inventors

• David D. Moore · Hingham, US
• Wongi Seol · Cambridge, US
• Hueng-Sik Choi · Gwangju, KR

Key dates

• Filing date: Jan 13, 1995
• Grant date: Aug 3, 1999
• Expiry date: Jan 13, 2015

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

Disclosed is a method for determining whether a test protein is capable of interacting with a retinoid X receptor protein. The method involves: (a) providing a host cell which contains (i) a reporter gene operably linked to a protein binding site; (ii) a first fusion gene which expresses a first fusion protein, the first fusion protein including a retinoid X receptor protein covalently bonded to a binding moiety which is capable of specifically binding to the protein binding site; and (iii) a second fusion gene which expresses a second fusion protein, the second fusion protein including the test protein covalently bonded to a gene activating moiety; and (b) determining whether the test protein increases expression of the reporter gene as an indication of its ability to interact with the retinoid X receptor protein. Also disclosed is purified DNA encoding retinoid X receptor-interacting proteins and the polypeptides expressed from such DNA.